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Investigation of LKB1 Ser431 phosphorylation and Cys433 farnesylation using
mouse knockin analysis reveals an unexpected role of prenylation in
regulating AMPK activity
Vanessa P. HOUDE*1, Maria Stella RITORTO*, Robert GOURLAY*, Joby VARGHESE*, Paul DAVIES*, Natalia SHPIRO*,
Kei SAKAMOTO*2 and Dario R. ALESSI*1
*MRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, U.K.
The LKB1 tumour suppressor protein kinase functions to activate
two isoforms of AMPK (AMP-activated protein kinase) and
12 members of the AMPK-related family of protein kinases.
The highly conserved C-terminal residues of LKB1 are phos-
phorylated (Ser431) by PKA (cAMP-dependent protein kinase)
and RSK (ribosomal S6 kinase) and farnesylated (Cys433) within a
CAAX motif. To better define the role that these post-translational
modifications play, we created homozygous LKB1S431A/S431A and
LKB1C433S/C433S knockin mice. These animals were viable, fertile
and displayed no overt phenotypes. Employing a farnesylation-
specific monoclonal antibody that we generated, we established
by immunoprecipitation that the vast majority, if not all, of the
endogenous LKB1 is prenylated. Levels of LKB1 localized at
the membrane of the liver of LKB1C433S/C433S mice and their
fibroblasts were reduced substantially compared with the wild-
type mice, confirming that farnesylation plays a role in mediating
membrane association. Although AMPK was activated normally
in the LKB1S431A/S431A animals, we unexpectedly observed in all of
the examined tissues and cells taken from LKB1C433S/C433S mice that
the basal, as well as that induced by the AMP-mimetic AICAR
(5-amino-4-imidazolecarboxamide riboside), AMPK activation,
phenformin and muscle contraction were significantly blunted.
This resulted in a reduced ability of AICAR to inhibit lipid
synthesis in primary hepatocytes isolated from LKB1C433S/C433S
mice. The activity of several of the AMPK-related kinases ana-
lysed [BRSK1 (BR serine/threonine kinase 1), BRSK2, NUAK1
(NUAK family, SNF1-like kinase 1), SIK3 (salt-inducible kinase
3) and MARK4 (MAP/microtubule affinity-regulating kinase
4)] was not affected in tissues derived from LKB1S431A/S431A or
LKB1C433S/C433S mice. Our observations reveal for the first time that
farnesylation of LKB1 is required for the activation of AMPK.
Previous reports have indicated that a pool of AMPK is localized at
the plasma membrane as a result of myristoylation of its regulatory
AMPKβ subunit. This raises the possibility that LKB1 farnesyla-
tion and myristoylation of AMPKβ might promote the interaction
and co-localization of these enzymes on a two-dimensional mem-
brane surface and thereby promote efficient activation of AMPK.
Key words: 5-amino-4-imidazolecarboxamide riboside (AICAR),
AMP-activated protein kinase-related kinase (AMPK-related
kinase), monoclonal antibody, phenformin, SAD-A/SAD-B
kinase, signal transduction.
INTRODUCTION
Inactivating mutations in the LKB1 kinase tumour suppressor
gene cause the inherited Peutz–Jeghers cancer syndrome, in which
patients are predisposed to developing benign and malignant tu-
mours [1]. Loss-of-function mutations in LKB1 are also observed
in certain sporadic cancers [2] especially lung adenocarcinomas
[3,4]. LKB1 is activated through its ability to form a heterotrimeric
complex with the pseudokinase STRAD (STE20-related kinase
adaptor) and the scaffolding protein MO25 [5–8].
Most data have suggested that LKB1 exerts its physiological
effects by phosphorylating and activating a group of 14 related
protein kinases that belong to the AMPK (AMP-activated
protein kinase) subfamily [9]. These include the two isoforms
of the AMPK catalytic subunit (AMPKα1 and AMPKα2),
which are activated following phosphorylation of their T-
loop residue (Thr172) by LKB1 [10–12]. One of the key
physiological/pathological conditions that leads to the activation
of AMPK is low energy, where increasing levels of AMP
and/or ADP interact with the CBS motifs of the regulatory
AMPKγ subunit of AMPK [13,14]. This induces conformational
changes that directly stimulate AMPKα catalytic activity through
allosteric mechanisms and also promote the phosphorylation of
Thr172 by inhibiting dephosphorylation of this residue by protein
phosphatases [15,16]. Once activated, AMPKα1 and AMPKα2
function to restore and maintain energy levels by phosphorylating
a myriad of proteins that control processes including cell growth
and proliferation and metabolism [17].
The 12 other kinases activated by LKB1 are collectively termed
the AMPK-related kinases [18]. LKB1 also activates the AMPK-
related kinases by phosphorylating the T-loop threonine residue
equivalent to AMPKα1/α2 Thr172 located within the kinase
Abbreviations: ACC, acetyl-CoA carboxylase; ACTH, adrenocorticotropic hormone; AICAR, 5-amino-4-imidazolecarboxamide riboside; AMPK, AMP-
activated protein kinase; ARK5, AMPK-related protein kinase 5; BDNF, brain-derived neurotrophic factor; BiP, immunoglobulin heavy-chain-binding
protein; BRSK, BR serine/threonine kinase; DMEM, Dulbecco’s modified Eagle’s medium; EDL, extensor digitorum longus; ER, endoplasmic reticulum;
ERK, extracellular-signal-regulated kinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HA, haemagglutinin; HEK, human embryonic kidney;
HRP, horseradish peroxidase; HSP90, heat-shock protein 90; MAPK, mitogen-activated protein kinase; MAPKAPK, MAPKAP (MAPK-activated protein)
kinase; MARK4, MAP/microtubule affinity-regulating kinase 4; MEF, mouse embryonic fibroblast; mTOR, mammalian target of rapamycin; NUAK1, NUAK
family, SNF1-like kinase; PDK1, phosphoinositide-dependent kinase 1; PH, pleckstrin homology; PI3K, phosphoinositide 3-kinase; PKA, cAMP-dependent
protein kinase; raptor, regulatory associated protein of mTOR; RSK, ribosomal S6 kinase; SIK3, salt-inducible kinase 3; STRAD, STE20-related kinase
adaptor; TBC1D1, TBC (Tre-2/Bub2/Cdc16) domain family, member 1.
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2 Current address: Nestle´ Institute of Health Sciences SA, Campus EPFL Quartier de l’innovation, baˆtiment G 1015 Lausanne, Switzerland.
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domains of these enzymes [18]. In contrast with AMPKα1 or
AMPKα2, the AMPK-related kinases do not possess adenine
nucleotide, such as AMP, -binding regulatory subunits and are
not stimulated by energy stress [9]. Previous studies have shown
that the AMPK-related kinases play critical roles in controlling
physiological processes such as polarity [19], adhesion [20],
proliferation [21] and CREB (cAMP-response-element-binding
protein)-mediated gene transcription [22,23].
LKB1 is phosphorylated and prenylated at a highly conserved
motif within its C-terminal residues. In mice the C-terminal
residues are KIRRLSACKQQ, corresponding to residues 426–
436 of mouse LKB1 in which the underlined Ser431 residue is
phosphorylated and the underlined Cys433 residue is farnesylated
[24–26]. The farnesylated cysteine residue lies within a CAAX
motif required for prenylation of all proteins [27,28]. LKB1
prenylation probably promotes association with the plasma
membrane as mutation of Cys433 to alanine or serine, to prevent
farnesylation, was shown to reduce levels of LKB1 associated
with the plasma membrane in several studies [20,25,29]. Ser431
is phosphorylated by the PKA (cAMP-dependent protein kinase)
in response to agonists that stimulate cAMP production or by
the p90 RSK (ribosomal S6 kinase) in response to stimuli that
trigger the activation of the ERK1 (extracellular-signal-regulated
kinase 1)/ERK2 MAPKs (mitogen-activated protein kinases) [24–
26,30]. The CAAX motif and the basic residues at the − 2, − 3
and − 5 positions from Ser431, required for phosphorylation by
PKA and p90 RSK, are evolutionarily conserved in mammals,
frogs, fish and insects suggesting that these play a fundamental
role. In Caenorhabditis elegans the orthologue of LKB1 [Par-4
(abnormal embryonic partitioning of cytoplasm 4)] possesses a
residue at its C-terminus that is equivalent Ser431, but lacks the
CAAX prenylation motif [29].
A splice variant of LKB1 termed LKB1short has been identified
in which the C-terminal 63 residues encompassing Ser431 and
Cys433 are replaced by a unique 39-residue sequence lacking
known phosphorylation and farnesylation sites [31–33]. Although
LKB1short is expressed in several tissues its levels are particular
high in haploid spermatids in the testis. Male mice possessing
reduced levels of LKB1 in all tissues, but that also lack expression
of LKB1short, are sterile [31,33,34]. More detailed analysis
revealed that these animals displayed a dramatically reduced
number of mature spermatozoa in the epididymis due to a defect
in spermatozoa release during spermiation [32,33].
How Ser431 phosphorylation or Cys433 prenylation affects the
function of LKB1 is not understood. Mutation of Ser431 has no
effect on the ability of LKB1 to associate with STRAD and MO25
or to phosphorylate and activate AMPK in vitro [6,31,35]. There is
also no evidence that prenylation regulates PKA-/RSK-mediated
phosphorylation or vice versa as mutation of Ser431 to alanine did
not affect the prenylation of Cys433 and nor did the mutation of
Cys433 inhibit the phosphorylation of Ser431 [26]. Overexpression
of LKB1[S431A] together with STRAD and MO25 in HeLa cells
that lack LKB1 inhibited the cell cycle to the same extent as wild-
type LKB1 [36]. In contrast, roles for Ser431 phosphorylation have
been proposed that include promoting axon specification in the
developing nervous system in response to BDNF (brain-derived
neurotrophic factor) by promoting the activation of BRSK1 (BR
serine/threonine kinase 1)/BRSK2 (also known as SAD-B/SAD-
A) [37,38]. Drosophila loss-of-function mutations in the Lkb1
gene caused defects in the polarity of the oocyte, and this was
rescued by low-level expression in the germ line of wild-type
LKB1, but not by mutation of the residue homologous with Ser431
(Ser535) [29].
In an attempt to better define the physiological roles that
C-terminal post-translational modification play we generated
knockin mice in which Ser431 was mutated to alanine to prevent
phosphorylation or Cys433 was mutated to serine to prevent
farnesylation. Although the homozygous LKB1S431A/S431A and
LKB1C433S/C433S mice exhibited no overt phenotypes, we found
that the LKB1C433S/C433S animals displayed lower levels of LKB1
at their membrane and, surprisingly, had significantly reduced
basal, as well as stimulated, AMPK activity in all of the tissues and
cells analysed. This provides the first evidence that the membrane
association of LKB1 is required for efficient activation of AMPK
in vivo. We discuss the possibility that myristoylation of the
AMPKβ subunit and farnesylation of LKB1 may promote
the interaction of these enzymes on a two-dimensional surface
of the plasma membrane, which could operate to facilitate the
activation of AMPK by LKB1.
MATERIALS AND METHODS
Materials
Complete protease inhibitor cocktail tablets were obtained from
Roche, AICAR (5-amino-4-imidazolecarboxamide riboside)
was from Apollo Scientific, 2-deoxy-D-[1-3H]glucose and D-
[14C]mannitol were from PerkinElmer, and [γ -32P]ATP and
Protein G–Sepharose were purchased from GE Healthcare.
Phosphocellulose P81 paper was from Whatman. [1-14C]Acetic
acid was obtained from American Radiolabeled Chemicals.
Phenformin, forskolin and PMA were purchased from Sigma.
All plasmids, antibodies and recombinant proteins that we have
generated for the present study are available on request from our
reagents website (https://mrcppureagents.dundee.ac.uk/).
Antibodies
The following antibodies were raised by the DSTT (Division
of Signal Transduction Therapy) at the University of Dundee in
sheep and affinity-purified against the indicated antigens: anti-
AMPKα1 (S524D 2nd bleed, CTSPPDSFLDDHHLTR, residues
355–369 of human AMPKα1) and anti-AMPKα2 (S525D 2nd
bleed, CMDDSAMHIPPGLKPH, residues 353–366 of human
AMPKα2) [10], and anti-LKB1 (S170D 2nd bleed, raised against
full-length mouse LKB1), anti-SIK3 (salt-inducible kinase 3)
(S226B, 3rd bleed, TDILLSYKHPEVSFSMEQAGV, residues
1349–1369 of human SIK3), anti-NUAK1 [NUAK family, SNF1-
like kinase 1; also known as ARK5 (AMPK-related protein kinase
5)] (S628B, 1st bleed, raised against full-length human NUAK),
anti-MARK4 (MAP/microtubule affinity-regulating kinase 4)
(S272B, 3rd bleed, MSSRTVLAPGNDRNSDTHGT, residues
1–20 of human MARK4), anti-phospho-TBC1D1 [TBC (Tre-
2/Bub2/Cdc16) domain family, member 1] Ser237, anti-TBC1D1
(S279C 1st bleed, raised against full-length human TBC1D1),
anti-BRSK1 (S222B 3rd bleed, MVAGLTLGKGPESPDGDVSV,
residues 1–20 of human BRSK1) and anti-BRSK2 (S223B
2nd bleed, LSWGAGLKGQKVATSYESSL, residues 655–
674 of human BRSK2). The anti-HA (haemagglutinin)
antibody was from Roche. The anti-LKB1 (catalogue number
3047), anti-phospho-LKB1 Ser431 (catalogue number 3482),
anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase;
catalogue number 2118), anti-HSP90 (heat-shock protein 90;
catalogue number 4874), anti-Na+ /K+ -ATPase (catalogue
number 3010), anti-phospho-AMPK Thr172 (catalogue number
2535), anti-AMPKα1/α2 (catalogue number 2532) anti-
phospho-raptor [regulatory associated protein of mTOR
(mammalian target of rapamycin)] Ser792 (catalogue number
2083), anti-raptor (catalogue number 2280), anti-phospho-ACC
(acetyl-CoA carboxylase) Ser79 (catalogue number 3661),
anti-ACC (catalogue number 3662), anti-NUAK1/ARK5
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(catalogue number 4458), anti-lamin A/C (catalogue number
2032), anti-EEA1 (early endosome antigen 1; catalogue
number 2411), anti-BiP [immunoglobulin heavy-chain-binding
protein; also known as GRP78 (78 kDa glucose-related protein)
catalogue number 3177], anti-LAMP1 (lysosomal-associated
membrane protein 1; catalogue number 3243), anti-phospho-
ERK1/2 Thr202/Tyr204 (catalogue number 4377) and anti-ERK1/2
(catalogue number 4695) were purchased from Cell Signaling
Technology. Secondary antibodies coupled to HRP (horseradish
peroxidase) were from Thermo Scientific. We also attempted
to analyse the expression of endogenous mouse LKB1 by
immunofluorescence. However, we were unable to identify
an antibody that was capable of specifically localizing LKB1
expression in wild-type MEFs (mouse embryonic fibroblasts)
in which no signal was observed in parallel experiments with
LKB1-knockout MEFs. The antibodies tested were anti-LKB1
(catalogue number 3047, rabbit monoclonal) from Cell Signaling
Technology and anti-LKB1 [Ley 37D/G6] (catalogue number
15095, mouse monoclonal) from Abcam. The protocol used was
as follows. Cells for immunofluorescence studies were grown on
glass coverslips. They were fixed in 4%paraformaldehyde for
10 min followed by permeabilization with 1% Nonidet P40
for 15 min. Blocking was performed with donkey serum for 1 h
and the cells were then incubated with primary antibodies diluted
in PBS containing 0.2% BSA and 0.02% sodium azide for
1 h at room temperature (20 ◦C). Cells were washed with PBS
containing 0.2% BSA and 0.02% sodium azide and incubated
with Alexa Fluor®-conjugated secondary antibodies (raised in
donkeys) for 1 h at room temperature. Cells were then washed
with PBS containing 0.2% BSA and 0.02% sodium azide
and the slides mounted with a mounting medium followed by
visualization with a confocal microscope.
Expression and purification of farnesyl transferase
The expression plasmid encoding the His-tagged recombinant
farnesyl transferase α and β subunits was from Dr Aymelt
Itzen (Max-Planck-Institute of Molecular Physiology, Dortmund,
Germany). It was transformed into Escherichia coli BL21 cells
and cultured at 37 ◦C with shaking until a D value of 0.8 was
achieved. Protein expression was induced with 100 μM IPTG for
4 h at 37 ◦C with shaking. Bacteria were pelleted by centrifugation
at 6500 g for 30 min at 4 ◦C. Cells were then resuspended in
17 ml of lysis buffer (50 mM sodium phosphate monobasic, pH 8,
300 mM NaCl, 1 mM PMSF and 1 mM benzamidine) per litre
of culture. Cells were lysed by sonication at 70% amplitude
for 1 min on ice and the resulting supernatant was clarified by
centrifugation at 31500 g. The supernatant was passed over a
10 ml chelating Sepharose IDA column (GE Life Sciences) loaded
with NiSO4. Unbound protein was washed from the column
using 10 bed volumes of lysis buffer or until the UV 280 value
returned to base levels. His-tagged proteins were eluted over a
0–500 mM imidazole gradient and the fractions containing the
protein pooled. Following buffer exchange on a Hiprep 26/10
desalting column (GE Life Sciences) into 25 mM Hepes (pH 7.2),
the pooled fraction was loaded on to a Hitrap Q column (GE Life
Sciences). After washing with 5 bed volumes of the loading buffer,
the protein was eluted over a 0–500 mM NaCl gradient. A final
purification across a G200 Sephadex column into 25 mM Hepes
(pH 7.2), 40 mM NaCl and 1 mM DTT resulted in a highly pure
and active enzyme.
Synthesis of farnesyl pyrophosphate
Farnesyl pyrophosphate was synthesized as described previously
[39].
Farnesylation and purification of the LKB1 peptide
The LKB1 peptide (CKIRRLSACKQQ) (synthesized by GL
Biochem) was farnesylated at 37◦C for 3 h in a prenylation buffer
containing 25 mM Hepes (pH 8.5), 40 mM NaCl, 2 mM MgCl2,
20 μM ZnCl2, 1 mM TCEP [tris(2-carboxyethyl)phosphine],
160 μM farnesyl pyrophosphate and 5 μM farnesyl transferase.
Isolation of the non-farnesylated from the farnesylated peptide
was done by SPE (solid-phase extraction) using STRATATM-
C18-E polymeric reversed phase end-capped C18 sorbent (for
strong hydrophobic retention by the active silanol groups)
cartridges (Phenomenex) at 25% (non-farnesylated), 60%
(farnesylated) and 100% acetonitrile/0.1% trifluoroacetic acid.
The presence and purity of the peptide in the different
fractions were tested by MALDI–TOF-MS (UltrafleXtreme,
Bruker Daltonics) using a mixture of α-cyano-4-hydroxycinnamic
acid and 2,5-dyhydroxybenzoic acid (1:1) as a matrix, in reflectron
positive mode. For external calibration, a mix of nine mono-
isotopic masses were used, i.e. bradykinin, [M + H]+ = 757.3992
Da; angiotensin II, [M + H]+ = 1046.5418 Da; angiotensin I,
[M + H]+ = 1296.6848 Da; substance P, [M + H]+ = 1347.7354
Da; bombesin, [M + H]+ = 1619.8223 Da; renin substrate,
[M + H]+ = 1758.9326 Da; ACTH (adrenocorticotropic hor-
mone) clip 1–17, [M + H]+ = 2093.0862 Da; ACTH clip
18–39, [M + H]+ = 2465.1983 Da; and somatostatin 28,
[M + H]+ = 3147.4710 Da (Bruker Daltonics).
To assess the efficiency of the reaction and thus the purity of
the peptide after the farnesylation reaction, the product was run
on an off-line HPLC Ultimate 3000 system (Thermo Scientific)
and the chromatograms were acquired using a VWD-3400RS
UV–Vis photometer at a wavelength of 214 nM. Samples were
run on a highly resolving C18 column (Gemini-C18, 3 μm,
110Å, 3 mm × 250 mm, Phenomenex) and peptide separation
was achieved with a flow rate of 0.20 ml/min (solvent A,
0.1% trifluoroacetic acid and solvent B, acetonitrile/0.08%
trifluoroacetic acid). A gradient (slope 5) spanning 0–100%
mobile phase B over 130 min was used.
Production and purification of an LKB1 farnesylation-specific
antibody
The purified LKB1 farnesylated peptide (10 mg) was used
by Dundee Cell Products to produce a mouse monoclonal
antibody that strongly recognized this antigen. The hybridoma
expressing the most sensitive immunoblotting antibody that
recognized farnesylated LKB1 was selected and antibody purified
accordingly to the company’s protocol.
Generation and genotyping of LKB1C433S/C433S and LKB1S431A/S431A
mice
TaconicArtemis generated the LKB1C433S/C433S and LKB1S431A/S431A
mice. The mice were generated and maintained on a C57BL/6J
background. Genotyping was performed by PCR using genomic
DNA isolated from ear biopsies. Primer 1 (5′-CTAGTGTGGC-
CAAGTCAGAGG-3′) and primer 2 (5′-AGACCAGCTTGCTC-
TGTTGG-3′) were used to detect the wild-type and knockin
alleles. The PCR program consisted of 5 min at 95◦C, then 35
cycles of 30 s at 95◦C, 30 s at 60◦C, 1 min at 72◦C and 10 min at
72◦C.
All animal studies and breeding was approved by the University
of Dundee ethical committee and performed under a U.K. Home
Office project licence.
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Intraperitoneal glucose- and AICAR-tolerance test
Mice were fasted for 6 h and injected intraperitoneally with
glucose (2 g/kg of body mass) or AICAR (250 mg/kg of body
mass) diluted in PBS. Blood was collected from the tail tip before
and at various times after injection. Blood glucose levels were
measured by an AlphaTrak glucometer (Abbott Laboratories).
Generation of MEFs and stimulations
LKB1C433S/C433S and LKB1S431A/S431A MEFs isolated from mouse
embryos at E13.5 (embryonic day 13.5) were generated as
described previously [40] and immortalized by continuous
passaging. Cells were cultured in DMEM (Dulbecco’s modified
Eagle’s medium) containing 10% FBS (Sigma), 2 mM L-
glutamine, 50 units/ml penicillin G and 50 μg/ml streptomycin
(Life Technologies). Cells were treated with AICAR (2 mM)
and phenformin (2 mM) for 1 h. Cells were washed with PBS
and lysed in ice-cold lysis buffer. Lysates were clarified by
centrifugation at 13000 g for 15 min at 4◦C, and the supernatant
was snap-frozen and stored at − 80◦C. The lysates (20 μg) in
SDS sample buffer were then subjected to immunoblotting.
LKB1+ / + and LKB1− / − MEFs, provided by Professor Tomi
Ma¨kela¨ (University of Helsinki, Helsinki, Finland) and described
previously [10], were cultured in DMEM containing 10%
FBS, 2 mM L-glutamine, 50 units/ml penicillin G and 50 μg/ml
streptomycin. Cells were stimulated with forskolin (20 μM) for
10 min or PMA (400 ng/ml) for 20 min. For lysis, cells were
washed with PBS and lysed in ice-cold lysis buffer. Lysates were
centrifuged at 13000 g for 15 min at 4◦C, and the supernatant
was snap-frozen and stored at − 80◦C. The lysates (20 μg) in
SDS sample buffer were then subjected to immunoblotting.
Transfection of HEK (human embryonic kidney)-293 cells
HEK-293 cells were transfected with a pCMV5-encoded DNA
construct expressing the plasmids indicated in the Figure legends.
At 36 h post-transfection cells were washed with PBS and lysed
in ice-cold lysis buffer. Lysates were centrifuged at 13000 g for
15 min at 4◦C, and the supernatant was snap-frozen and stored
at − 80◦C. The lysates (20 μg) in SDS sample buffer were then
subjected to immunoblotting.
Subcellular fractionation of mouse livers and MEFs
Mouse liver (50 mg) or 20 μl of packed MEFs were subjected
to subcellular fractionation using commercial kits (catalogue
numbers 87790 and 78840, Thermo Scientific). Cytoplasmic,
membrane and soluble nuclear fractions were prepared accord-
ingly to the manufacturer’s protocol using the buffers provided.
The amount of protein in each fraction was quantified using the
Bradford assay and then subjected to immunoblot analysis.
Primary hepatocyte isolation and treatment
Mouse primary hepatocytes were isolated as described previously
[41]. Isolated primary hepatocytes were plated in M199
medium (Invitrogen) containing 10% FBS (Sigma), 0.1%
BSA (Invitrogen), 10 nM insulin (Novo-Nordisk), 200 nM
tri-iodothyronine (Sigma), 500 nM dexamethasone (Sigma),
50 units/ml penicillin G and 50 μg/ml streptomycin (Life
Technologies) and then left to attach for 4 h at 37◦C in a 5%
CO2 atmosphere. The medium was then replaced for serum-free
M199 medium containing 100 nM dexamethasone. The next day,
cells were treated with an increased concentration of AICAR for
1 h, lysed and submitted to immunoblotting.
Preparation of tissue lysates
Mouse tissues were rapidly excised, frozen in liquid nitrogen and
stored at − 80◦C. Tissues were subsequently homogenized on ice
using a Kinematica Polytron in a 10-fold mass excess of ice-cold
lysis buffer containing 50 mM Tris/HCl (pH 7.5), 1 mM EDTA,
1 mM EGTA, 1% Triton X-100, 1 mM sodium orthovanadate,
50 mM NaF, 5 mM sodium pyrophosphate, 0.27 M sucrose, 0.1%
2-mercaptoethanol and Complete protease inhibitor cocktail.
Tissues lysates were clarified by centrifugation at 13000 g for
15 min at 4◦C. Supernatants were removed, snap-frozen and
stored at − 80◦C.
Incubation of isolated muscle with AICAR
Mice were killed by cervical dislocation and their EDL (extensor
digitorum longus) muscles were rapidly removed. Tendons from
both ends of each muscle were tied with suture and mounted on
an incubation apparatus. The muscles were incubated with 2 mM
AICAR as described previously [42].
In situ muscle contraction
Mice were anaesthetized with sodium pentobarbital (90 mg/kg of
body mass, administrated intraperitoneally), the sciatic nerves of
both legs were surgically exposed and electrodes were attached.
Muscle contraction was performed as described previously [34].
Glucose transport in isolated skeletal muscle
Mice were killed by cervical dislocation and their EDL muscles
were rapidly removed. Tendons from both ends of each muscle
were tied with suture, mounted on an incubation apparatus and
incubated as previously described to study the effect of AICAR
stimulation on glucose uptake [34]. To study the effect of in situ
muscle contraction on glucose uptake, sciatic nerve stimulation
was performed as in [34], the EDL muscle was isolated and then
2-deoxy-glucose uptake was measured.
Immunoblotting
Tissues or cell lysates (20 μg) were heated in SDS sample
buffer and subjected to SDS/PAGE (8 or 10% gel) followed
by electrotransfer on to nitrocellulose membranes. Membranes
were blocked in TBST [50 mM Tris/HCl (pH 7.5), 0.15 mM NaCl
and 0.1% Tween] containing 5% non-fat dried skimmed milk
powder for 1 h. The membranes were then probed with the primary
antibody (1 μg/ml for the sheep antibodies or 1000-fold dilution
for the commercial antibodies) for 16 h at 4◦C in TBST containing
5% non-fat dried skimmed milk powder (sheep antibodies)
or 5% BSA (commercial antibodies). Detection of protein
was performed using HRP-conjugated secondary antibodies and
an ECL reagent. Increasing amounts of non-farnesylated and
farnesylated LKB1 peptides were spotted on to nitrocellulose
membrane and then probed for 16 h with the anti-LKB1
farnesylation-specific antibody or anti-LKB1 antibodies at 4◦C in
TBST containing 5% non-fat dried skimmed milk powder (sheep
antibodies) or 5% BSA (commercial antibodies). Detection
of protein was performed using HRP-conjugated secondary
antibodies and an ECL reagent. Quantitative immunoblot analysis
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was performed by Li-Cor analysis. Briefly, blots were processed
as above, but incubated with a fluorescent secondary antibody
allowing for detection with the Li-Cor Odyssey infrared system.
Band intensity was quantified using Li-Cor software.
Immunoprecipitation and kinase activity
Tissues or cell lysates (0.05–2 mg) were incubated at 4◦C for 1 h
on a shaking platform with 5 μl of protein G–Sepharose coupled
to anti-LKB1, anti-AMPKα1, anti-AMPKα2, anti-SIK3, anti-
NUAK1, anti-MARK4, anti-BRSK1 and anti-BRSK2 (sheep)
antibodies. The immunoprecipitates were washed twice with
1 ml of lysis buffer containing 0.5 M NaCl and twice with
buffer A [50 mM Tris/HCl (pH 7.5), 0.1 mM EGTA and 0.1%
2-mercaptoethanol]. Phosphotransferase activity towards the
LKBtide peptide (SNLYHQGKFLQTFCGSPLYRRR) for LKB1,
AMARA peptide (AMARAASAAALARRR) for AMPKα1 and
AMPKα2, or Sakamototide substrate (ALNRTSSDSALHRRR)
[43] for SIK3, NUAK1, MARK4 and BRSK1/BRSK2, were
measured in a total assay volume of 50 μl consisting of 50 mM
Tris/HCl (pH 7.5), 0.1 mM EGTA, 0.1% 2-mercaptoethanol,
10 mM magnesium acetate, 0.1 mM [γ 32P]ATP and 200 μM
LKBtide peptide, AMARA peptide or Sakamototide substrate.
The assays were carried out at 30◦C with continuous shaking to
keep the immunoprecipitates in suspension and were terminated
after 20 min by applying 40 μl of the reaction mixture on to
p81 paper. These were washed in phosphoric acid and the
incorporated radioactivity was measured by scintillation counting.
One milliunit of activity was defined as that which catalysed the
incorporation of 1 pmol of 32P into the substrate per min. To assess
LKB1 activity by measuring the activation of an AMPK complex,
endogenous LKB1 was immunoprecipitated from mouse tissue
lysates (0.5 mg) as described above and incubated with 0.3 μg of
dephosphorylated inactive E. coli-expressed recombinant AMPK
complex (α1β2γ 1 subunits) as described previously [8].
Measurement of lipid synthesis from [14C]acetate
Primary hepatocytes were seeded in six-well plates. After an
overnight incubation in serum-free M199 medium containing
100 nM dexamethasone, hepatocytes were labelled for 1 h with
1 mM acetate and 0.5 μCi/ml [1-14C]acetic acid in the presence
or absence of increasing concentrations of AICAR. Cells were
washed three times with ice-cold PBS and then scraped into
chilled PBS. Primary hepatocytes were pelleted by centrifugation
at 2000 g for 2 min. A methanol/chloroform lipid extraction was
performed on the cell pellets. After the extraction, the insoluble
material (pellet) was dissolved in 0.5 M NaOH/0.5% SDS in
order to quantify the amount of protein per well. The solvent
found in the supernatant was evaporated and the incorporation of
[14C] into the lipid was measured by scintillation counting. The
incorporation rate was defined in units of μmol of acetate/g of
protein per h.
Identification of LKB1-interacting protein by MS
Tissue lysates (50 mg) were pre-cleared by incubation with 100 μl
of pre-immune IgG covalently coupled to Protein G–Sepharose
for 1 h at 4◦C on a rolling shaker. The supernatants were
then incubated with 50 μg of anti-LKB1 farnesylation-specific
antibody covalently coupled to Protein G–Sepharose for 1 h at
4◦C on a rolling shaker. The immunoprecipitates were washed
three times with 10 ml of lysis buffer containing 0.5 M NaCl and
twice with 10 ml of buffer A. The beads were resuspended in
a total volume of 30 μl of LDS sample buffer (Invitrogen). The
samples were then filtered with a 0.44 μm Spin-X filter (Corning),
reduced with 10 mM DTT, boiled and subjected to electrophoresis
on a NuPAGE Bis-Tris 4–12% polyacrylamide gel. Colloidal
Coomassie-stained gels were divided and each piece was washed
with 0.1 M NH4HCO3 and 50% acetonitrile/50 mM NH4HCO3,
alkylated with 50 mM iodoacetamide in 0.1 M NH4HCO3 (30 min
at room temperature), washed as above, dried, and incubated
with 25 mM triethylammonium bicarbonate with 5 μg/ml trypsin
overnight at 30◦C on a shaker. The resulting peptides were
submitted to LC–MS on a Proxeon EASY-nLC nano-LC system
coupled to a Thermo-LTQ-Orbitrap mass spectrometer. Data files
were searched against the SwissProt mouse database using Mascot
(http://www.matrixsciences.com) run on an in-house system, with
a 10 p.p.m. mass accuracy for precursor ions, a 0.6 Da tolerance for
fragment ions, and allowing for carbamidomethyl (C) as a fixed
modification and for oxidation and dioxidation (M) as variable
modifications.
RESULTS
Generation of a monoclonal antibody recognizing farnesylated
LKB1
To generate an antibody that recognized farnesylated LKB1,
we prenylated a peptide encompassing the C-terminal motif
of LKB1 using recombinant farnesyl transferase and farnesyl
pyrophosphate (Figure 1A). The prenylated peptide was purified
by chromatography, characterized by HPLC and MALDI–TOF-
MS (Figures 1B and 1C) and used to raise a mouse monoclonal
antibody. A hybridoma was identified that strongly recognized
the prenylated peptide, but not the non-prenylated peptide
(Figure 1D). This antibody recognized overexpressed wild-type
human and mouse LKB1, but not mutants in which the farnesyla-
tion was prevented by mutating Cys433 to serine (Figure 1E).
Evidence that the bulk of endogenous LKB1 is prenylated
To investigate whether the majority of endogenous LKB1 was
prenylated, we undertook immunoprecipitation studies using the
anti-LKB1 farnesylation-specific antibody on samples from mice
muscle, liver, brain and testis as well as MEFs. These experiments
were analysed by immunoblot analysis (Supplementary Figure
S1 at http://www.biochemj.org/bj/458/bj4580041add.htm) or
MS (Supplementary Table S1 at http://www.biochemj.org/bj/
458/bj4580041add.htm). This revealed that the anti-LKB1
farnesylation-specific antibody immunoprecipitated the vast
majority of endogenous LKB1 from all tissues/MEF extracts
examined. Immunoblot analysis of the supernatant of anti-LKB1
farnesylation-specific antibody immunoprecipitates revealed that
a relatively small portion of LKB1 that was not immunoprecipi-
tated was still prenylated. Analysing the anti-LKB1 farnesylation-
specific antibody immunoprecipitates by MS confirmed that
LKB1 and its regulatory STRAD and MO25 subunits were co-
immunoprecipitated. Moreover, in addition to LKB1, 13 other
proteins with C-terminal CAAX motifs, that are therefore likely
to be farnesylated, were immunoprecipitated including MAP-
KAPK3 [MAPKAP (MAPK-activated protein) kinase-3] that, to
our knowledge, has not been previously reported to be farne-
sylated (Supplementary Tables S1 and S2 at http://www.biochemj.
org/bj/458/bj4580041add.htm). The anti-LKB1 farnesylation-
specific antibody may also recognize geranylgeranylated pren-
ylated proteins, as we found at least eight Rab GTPase isoforms
co-immunoprecipitating with the anti-LKB1 farnesylation-
specific antibody that are modified by introduction of two
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Figure 1 Generation of a monoclonal antibody recognizing farnesylated LKB1
(A) Diagram illustrating the structure of the mouse LKB1 protein as well as the peptide used for the antibody production (antigen) with the farnesyl moiety attached to the C-terminal cysteine (Cys433).
(B) HPLC chromatogram and (C) MALDI–TOF-MS of the peptide containing Cys433 before and after the farnesylation reaction. (D) Dot-blot analysis demonstrating that the anti-LKB1 farnesylated
at Cys433 antibody does not recognize the C-terminal cysteine on the wild-type (WT) peptide (non-farnesylated peptide). Farn peptide, farnesylated peptide; IB, immunoblot. (E) HEK-293 cells were
transfected with the indicated mouse and human HA–LKB1 mutants. The samples were immunoblotted with the anti-LKB1 farnesylated at Cys433 antibody to ensure that the antibody does not
recognize the cysteine mutant proteins. Molecular mass is given on the left-hand side in kDa.
geranylgeranyl groups on to two cysteine residues at the C-
terminal consensus sequence, XCXC or XXCC, which is intro-
duced by the Rab geranylgeranyl transferase [44] (Supplementary
Tables S1 and S2). A sequence alignment of the six C-
terminal residues of each prenylated protein co-immunoprecipi-
tated with the anti-LKB1 farnesylation-specific antibody is also
shown in Supplementary Table S2.
Characterization of the farnesylation-deficient LKB1C433S/C433S
mouse
Knockin mice in which the LKB1 farnesylated Cys433 is changed
to serine to abolish prenylation were generated and maintained
on an inbred C57BL/6J background as shown in Figure 2(A).
Homozygous LKB1C433S/C433S mice were born at the expected
Mendelian frequency (Figure 2B), were of normal size and
appearance, and did not display any overt phenotype at least
up to 1 year of age (the oldest animals we have analysed).
Immunoblot analysis using the anti-LKB1 farnesylation-specific
antibody confirmed that LKB1 was no longer prenylated
in tissues or MEFs derived from the LKB1C433S/C433S mice
(Figures 2C and 2D). Immunoprecipitation studies with the anti-
LKB1 farnesylation-specific antibody also confirmed that LKB1,
STRAD and MO25 were immunoprecipitated from various
tissues (brain, liver, muscle and testis) and MEFs from wild-
type, but not LKB1C433S/C433S, mice in experiments conducted
in parallel (Supplementary Figure S1 and Supplementary Table
S1 at http://www.biochemj.org/bj/458/bj4580041add.htm). Total
LKB1 immunoblot analysis also revealed that the LKB1[C433S]
mutant was expressed at similar levels to the wild-type LKB1 in
the liver, muscle, spleen, kidney and MEFs (Figure 2C).
Farnesylation of LKB1 in the testis
We also immunoblotted testis, which, as mentioned in the
Introduction section, expresses a high level of the LKB1short
isoform that lacks the C-terminal prenylation motif. Immunoblot
analysis revealed that the levels of LKB1short were not affected
significantly in the testis of LKB1C433S/C433S mice (Figure 2D).
Immunoprecipitation studies with the anti-LKB1 farnesylation-
specific antibody confirmed that the normal LKB1long isoform
was immunoprecipitated, but not the LKB1short isoform, which is
not farnesylated [31–33] (Supplementary Figure S1). However,
in contrast with other tissues, we found that the levels of the
LKB1long isoform were expressed at approximately 2-fold higher
levels in the testis of LKB1C433S/C433S mice compared with their
littermate wild-type mice (Figure 2D). The reasons for this are
not clear and require further investigation. The LKB1C433S/C433S
mice are fertile as crosses of homozygous LKB1C433S/C433S animals
resulted in viable offspring.
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Figure 2 Characterization of the farnesylation-deficient LKB1C433S/C433S mouse
(A) The knockin construct, the endogenous LKB1 allele containing exons 1–10 and the target allele with the puromycin cassette (Puro) removed by Flp (flippase) recombinase are depicted. The
black/grey rectangles represent exons and the black triangles represent FRT (flippase-recognition target) sites. TK, thymidine kinase. (B) To genotype mice, genomic DNA was PCR-amplified. Sizes
are indicated in bp. The breeding strategy employed to generate LKB1C433S/C433S mice is shown with the number and percentage of each genotype obtained indicated. (C) Tissues lysates from
wild-type LKB1+ / + and LKB1C433S/C433S mice and MEFs were subjected to immunoblotting using anti-LKB1 and anti-LKB1 farnesylation-specific (LKB1 Farn C433) antibodies. (D) Testis lysates
from LKB1+ / + and LKB1C433S/C433S mice were immunoblotted with an anti-LKB1 antibody to detect the LKB1long (LKB1L) and LKB1short (LKB1s) isoforms. Band intensities were quantified using
Li-Cor. Results are means +− S.E.M. for four mice per genotype. (E) LKB1 was immunoprecipitated (IP) from the liver and muscle (EDL) from wild-type LKB1+ / + ( + / + ) and LKB1C433S/C433S
(C433S/C433S) mice and the in vitro kinase activity towards the LKBtide peptide was measured. Immunoprecipitates were also immunoblotted (IB). Assays were performed in duplicate from
tissues taken from six mice per genotype and the results are means +− S.E.M. The broken line represents the background activity as measured with pre-immune IgG. (F) As (E), except that the
immunoprecipitated LKB1 protein was used to activate a recombinant heterotrimeric AMPK complex (α1β2γ 1) and then AMPK kinase activity towards the AMARA peptide was measured. Assays
were performed in duplicate from tissues taken from six mice per genotype and the results are means +− S.E.M. (G) Liver and MEFs from wild-type (WT) LKB1+ / + ( + / + ) and LKB1C433S/C433S
(KI/KI) mice were submitted to subcellular fractionation. Cytoplasmic, membrane and nuclear fractions were immunoblotted with the indicated antibodies. Blots for two animals out of four per
genotype are shown.
Farnesylation does not influence LKB1 catalytic activity
To assess how the C433S mutation affected the kinase activity
of LKB1 we immunoprecipitated endogenous LKB1 from the
muscle and liver and studied its kinase activity employing either
the LKBtide peptide substrate, derived from the NUAK2 T-loop
motif [18] (Figure 2E) or a recombinant full-length heterotrimeric
AMPKα1–AMPKβ2–AMPKγ 1 complex expressed in E. coli
cells (Figure 2F). This revealed that whichever way LKB1
catalytic activity was assessed, loss of farnesylation had no effect
on catalytic activity.
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Evidence that farnesylation of LKB1 promotes membrane
localization
To assess whether loss of LKB1 farnesylation affected membrane
localization, we fractionated liver and MEF (Figure 2G, upper
and lower panel respectively) extracts, derived from littermate
wild-type and LKB1C433S/C433S knockin mice, into cytoplasmic,
membrane and nuclear fractions and analysed the relative levels of
LKB1 by immunoblot analysis. Consistent with previous findings
[20,25,29] in samples derived from wild-type mice, significant
levels of LKB1 were present in the cytoplasmic and membrane
fractions with only low levels of LKB1 observed in the nuclear
fractions. Immunoblotting with the anti-LKB1 farnesylation-
specific antibody revealed that the LKB1 present in all fractions
was farnesylated and, consistent with the bulk of LKB1 being
prenylated, the relative signal observed paralleled the total
expression of LKB1. However, consistent with the notion that the
farnesylation of LKB1 promotes association with membranes, we
observed that the levels of LKB1 in the membrane fractions were
significantly reduced in the livers and MEFs of LKB1C433S/C433S
mice compared with the wild-type (Figure 2G). We also observed
a reduction in non-farnesylated LKB1 in the nuclear fraction of the
livers and MEFs of LKB1C433S/C433S mice compared with the wild-
type (Figure 2G). It should be noted that the fractions labelled
cytoplasmic in Figure 2(G) also contained endomembranes as
assessed by immunoblot analysis of ER (endoplasmic reticulum),
endosome and lysosome markers (Supplementary Figure S2 at
http://www.biochemj.org/bj/458/bj4580041add.htm). Moreover,
the fraction labelled membrane was also contaminated with ER as
identified using immunoblot analysis with a GRP78/BiP marker
(Supplementary Figure S2). We also attempted to analyse the
expression of endogenous mouse LKB1 by immunofluorescence.
However, we were unable to identify an antibody that was capable
of specifically localizing LKB1 expression in wild-type MEFs in
which no signal was also observed in the LKB1-knockout MEFs
examined in parallel experiments (a list of the antibodies tested is
provided in the Materials and methods section).
Impaired activity of AMPK and lipid synthesis in primary
hepatocytes derived from LKB1C433S/C433S mice
To establish whether loss of LKB1 farnesylation affected
the activity of AMPK, we isolated primary hepatocytes from
LKB1C433S/C433S and littermate wild-type mice. These were
left either unstimulated or treated with increasing doses of
AICAR [45], a compound that is metabolized within the cells
to ZMP (5-aminoimidazole-4-carboxamide-1-β-D-furanosyl 5′-
monophosphate), an analogue of AMP capable of stimulating
AMPK via an LKB1-dependent mechanism [10,11]. Under basal
conditions, we unexpectedly observed that AMPK activity and
phosphorylation of its T-loop Thr172 residue (phosphorylated by
LKB1) was reduced in the LKB1C433S/C433S hepatocytes compared
with the wild-type (Figure 3A). In hepatocytes from the wild-
type animals, AICAR induced a robust activation of AMPK that
was accompanied by increased phosphorylation of AMPK at
Thr172. In hepatocytes derived from LKB1C433S/C433S mice, AICAR
treatment only partially stimulated AMPK activity and T-loop
phosphorylation compared with the wild-type (Figure 3A).
Consistent with this, phosphorylation of raptor, a known bona fide
AMPK substrate [46], at Ser792 was also significantly repressed
in AICAR-stimulated LKB1C433S/C433S hepatocytes (Figure 3A). In
contrast, monitoring the phosphorylation of ACC we observed no
significant difference between the wild-type and LKB1C433S/C433S
knockin hepatocytes. AICAR treatment did not affect LKB1
farnesylation in wild-type hepatocytes (Figure 3A).
An established physiological consequence of AMPK activation
in hepatocytes is to inhibit lipid synthesis [47]. Consistent
with this notion, reduced activation of AMPK in LKB1C433S/C433S
hepatocytes in response to AICAR resulted in blunted AICAR-
mediated suppression of lipid synthesis compared with wild-type
hepatocytes (Figure 3B).
Impaired activity of AMPK in muscle from LKB1C433S/C433S mice
We next assessed the level of AMPK activity and T-loop
phosphorylation in skeletal muscle of littermate wild-type and
LKB1C433S/C433S mice. Muscle AMPK was stimulated by in
situ contraction evoked via electrical stimulation of the sciatic
nerve for one leg and the other leg served as the sham-
operated non-stimulated control. As in unstimulated or AICAR-
stimulated hepatocytes (Figure 3), we observed a significantly
reduced basal, as well as contraction-induced, AMPK activity
(Figure 4A) and T-loop phosphorylation (Figure 4B) in muscle
taken from LKB1C433S/C433S compared with wild-type mice. This
reduced AMPK activation was also accompanied by a decreased
phosphorylation of the AMPK substrates ACC [48], raptor [46]
and TBC1D1 [49] at residues that are phosphorylated by AMPK.
Phosphorylation of the ERK1 and ERK2 protein kinases induced
by contraction [50], which is not regulated via AMPK, was not
affected by the LKB1C433S/C433S mutation (Figure 4B).
One of the major consequences of AMPK activation in
skeletal muscle is to stimulate glucose uptake via translocation
of GLUT4 (glucose transporter type 4) to the plasma membrane
[51]. Previous work has shown that this translocation is very
sensitive to AMPK, and even very low levels of AMPK activation
are sufficient to induce maximal glucose uptake [34,52]. This
probably explains why, despite reduced activation of AMPK in
muscle from LKB1C433S/C433S mice, contraction-induced glucose
uptake was unaffected (Figure 4C). Similarly, we observed that
AICAR treatment of isolated EDL muscle from LKB1C433S/C433S
mice resulted in a significant reduction in AMPK activation
(Figure 4D) and T-loop and substrate phosphorylation compared
with muscle from the wild-type mice (Figure 4E) without affecting
glucose uptake (Figure 4F).
We also subjected 2-month-old LKB1C433S/C433S mice to glucose-
and AICAR-tolerance tests, which revealed that these animals
did not display significant intolerance compared with the wild-
type mice (Supplementary Figure S3 at http://www.biochemj.org/
bj/458/bj4580041add.htm). Muscle contraction did not affect the
farnesylation of LKB1 in muscle from wild-type mice (Figures 4B
and 4E). We also generated MEFs derived from LKB1C433S/C433S
mice and observed a reduced activation of AMPK in basal, as well
in AICAR- and phenformin-treated, cells (Supplementary Figure
S4 at http://www.biochemj.org/bj/458/bj4580041add.htm).
Characterization of the LKB1S431A/S431A mouse
Knockin mice in which the Ser431 that is phosphorylated by PKA
and RSK was changed to an alanine to prevent phosphorylation
were created and maintained on an inbred C57BL/6J background
(Figure 5A). Homozygous LKB1S431A/S431A mice were born at the
expected Mendelian frequency (Figure 5B), were of normal size
and appearance, and did not display any overt phenotype at least
up to 1 year of age (the oldest animals we have analysed).
The LKB1S431A/S431A mice are fertile as crosses of homozygous
LKB1S431A/S431A animals resulted in viable offspring.
Immunoblot analysis revealed that the LKB1[S431A] mutant
was expressed at similar levels to wild-type LKB1 in all of the
tissues studied, including the LKB1long and LKB1short forms in
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Figure 3 Impaired activity of AMPK and lipid synthesis in primary hepatocytes derived from LKB1C433S/C433S mice
Primary hepatocytes were isolated from wild-type LKB1+ / + ( + / + ) and LKB1C433S/C433S (KI/KI) mice and treated with increasing concentrations of AICAR for 1 h. (A) Upper panel: AMPKα1 was
immunoprecipitated from primary hepatocytes extracts and the in vitro kinase activity towards the AMARA peptide was measured. Assays were performed in duplicate for each condition and results
are means +− S.E.M. for three independent experiments (n = 3). For the non-stimulated conditions the P value of the data for LKB1+ / + compared with LKB1C433S/C433S mice was 0.1 and therefore
judged not to be significant. The broken line represents the background activity as measured with pre-immune IgG. Lower panel: primary hepatocyte extracts were immunoblotted with the indicated
antibodies. Representative immunoblots for three independent experiments (n = 3) are shown. LKB1 Farn C433, anti-LKB1 farnesylation-specific antibody. (B) Lipogenesis following AICAR treatment
in primary hepatocytes was assessed by using [14C]acetate incorporation. Assays were performed in triplicate for each condition and results are means +− S.E.M. for four independent experiments
(n = 4). *P < 0.05 LKB1+ / + compared with LKB1C433S/C433S mice within each condition and #P < 0.05 treatment compared with non-treatment condition. Statistical analysis was performed using
one-way ANOVA and Tukey’s post-hoc test.
testis as well as in MEFs (Figure 5C). Employing an antibody that
recognizes LKB1 phosphorylated at Ser431 we observed that treat-
ment of LKB1+ / + wild-type MEFs with either forskolin to
activate PKA or PMA to stimulate RSK, induced, as expected, a
marked phosphorylation of LKB1 at Ser431 (Figure 5D). In parallel
experiments, stimulation of LKB1S431A/S431A MEFs with forskolin
or PMA, as predicted, did not result in increased detection of
LKB1 with the phospho-Ser431 antibody. It should be noted that
the commercial phospho-Ser431 antibody used was the only one
we tested that worked well in recognizing mouse LKB1 and
also weakly recognized non-phosphorylated LKB1[S431A] in
the immunoblot analysis of the LKB1S431A/S431A MEFs. This weak
signal was unchanged following stimulation of LKB1S431A/S431A
MEFs with forskolin or PMA and was also lost in LKB1-
knockout MEFs (Figure 5D, lower panel). High levels of LKB1
Ser431 phosphorylation were detected in the spleen, but not in the
liver, muscle or kidney of wild-type mice (Figure 5C).
AMPK is activated normally in LKB1S431A/S431A tissues and MEFs
To assess how the S431A mutation affected LKB1 kinase activity,
we immunoprecipitated endogenous LKB1 from muscle and liver
extracts and studied kinase activity using the LKBtide peptide
substrate. This revealed that loss of Ser431 phosphorylation had
no effect on catalytic activity (Figure 5E). We next assessed the
level of AMPK activity and T-loop phosphorylation in the liver
and muscle of littermate wild-type and LKB1S431A/S431A mice. This
revealed that the mutation had no significant effect on the basal
activity of AMPK (Figures 5C and 5F).
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Figure 4 Impaired activity of AMPK in muscles taken from LKB1C433S/C433S mice
(A) One leg from anaesthetized wild-type LKB1+ / + ( + / + ) and LKB1C433S/C433S (C433S/C433S) mice was subjected to in situ hindlimb contraction (Contraction) via sciatic nerve stimulation for
5 min and the other leg served as a non-contracted control (Basal). AMPKα2 was immunoprecipitated (IP) from tibialis anterior lysates and the in vitro kinase activity towards the AMARA peptide
was measured. The immunoprecipitates were also immunoblotted (IB). Assays were performed in duplicate from lysates derived from five mice per genotype and results are means +− S.E.M. The
broken line represents the background activity as measured with pre-immune IgG. (B) Tibialis anterior muscle lysates were submitted to immunoblotting with the indicated antibodies. A total of
three animals out of five per genotype are shown (n = 5). (C) Following contraction, EDL muscles were isolated and glucose transport was measured. Results are means +− S.E.M. (n = 4–7 per
group). (D) Isolated EDL muscle taken from wild-type LKB1+ / + ( + / + ) and LKB1C433S/C433S (C433S/C433S) mice were incubated in the presence or absence of 2 mM AICAR for 50 min. AMPKα2
was immunoprecipitated from EDL lysates and the in vitro kinase activity towards the AMARA peptide was measured. The immunoprecipitates were also immunoblotted. Assays were performed in
duplicate from lysates derived from four to five mice per genotype and results are means +− S.E.M. The broken line represents the background activity as measured with pre-immune IgG. (E) EDL
muscle lysates were submitted to immunoblotting with the indicated antibodies. A total of three animals out of five per genotype are shown (n = 5). (F) Glucose transport in isolated EDL muscle
was measured. Results are means +− S.E.M. (n = 4–7 per group). *P < 0.05 basal compared with contraction or AICAR stimulation within each genotype. Statistical analysis was performed using
one-way ANOVA and Tukey’s post-hoc test.
We also stimulated wild-type and LKB1S431A/S431A-knockin
MEFs with AICAR and phenformin and observed that mutation
of Ser431 had no effect on the activation of AMPKα1 or
AMPK T-loop phosphorylation induced by either of agonist
(Figure 6A). We also investigated by subcellular fractionation
whether mutation of Ser431 affected the localization of LKB1 in
the liver (Figure 6B) and MEFs (Figure 6C). This revealed that the
mutation of Ser431 had no significant effect on the amount of LKB1
present within the cytoplasmic, membrane and nuclear fractions
analysed. Moreover, stimulation of MEFs with forskolin to induce
phosphorylation of Ser431 also had no effect on the fraction of
LKB1 between the cytoplasmic, membrane and nuclear fractions
(Figure 6C).
AMPK-related kinases are activated normally in LKB1C433S/C433S and
LKB1S431A/S431A mice tissues
We also measured the activity of five endogenous AMPK-
related kinases (SIK3, NUAK1, MARK4, BRSK1 and BRSK2)
after their immunoprecipitation from the liver, muscle and
brain extracts obtained from littermate wild-type, LKB1C433S/C433S
and LKB1S431A/S431A mice. This revealed that mutation of Ser431
or Cys433 had no effect on the activity of these AMPK-
related protein kinases (Supplementary Figures S5 and S6 at
http://www.biochemj.org/bj/458/bj4580041add.htm).
DISCUSSION
The role of LKB1 farnesylation has intrigued since it was
first reported over 13 years ago [25,26]. To date the only data
indicating a role for LKB1 farnesylation was immunofluorescence
localization and subcellular fractionation studies employing
overexpressed LKB1 that suggested that mutation of Cys433 to
prevent farnesylation inhibited the association of LKB1 with
the plasma membrane [20,25,29]. As mentioned in the Results
section, we were unable to identify a suitable antibody to localize
endogenous mouse LKB1 in immunofluorescence studies that
did not bind and therefore signal in LKB1-knockout MEFs. It
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Figure 5 Characterization of the LKB1S431A/S431A mouse
(A) The knockin construct, the endogenous LKB1 allele containing exons 1–10 and the target allele with the puromycin cassette (Puro) removed by Flp recombinase are shown. The black/grey
rectangles represent exons and the black triangles represent FRT (flippase-recognition target) sites. TK, thymidine kinase. (B) To genotype mice, genomic DNA was PCR-amplified. Sizes are indicated
in bp. The breeding strategy employed to generate LKB1S431A/S431A mice is shown with the number and percentage of each genotype obtained indicated. (C) Tissues lysates from wild type LKB1+ / +
and LKB1S431A/S431A mice were subjected to immunoblotting using anti-LKB1 and anti-phospho-LKB1 Ser431 antibodies. (D) MEFs derived from wild-type LKB1+ / + and LKB1S431A/S431A mice (upper
panel) or wild type LKB1+ / + ( + / + ) and knockout LKB1− / − ( − / − ) mice (lower panel) were stimulated with forskolin (20 μM for 10 min) or TPA (400 ng/ml for 20 min) and immunoblotted
with the indicated antibodies. (E) LKB1 was immunoprecipitated (IP) from the liver and muscle (EDL) from wild-type LKB1+ / + ( + / + ) and LKB1S431A/S431A (S431A/S431A) mice and the in vitro
kinase activity towards the LKBtide peptide was measured. Immunoprecipitates were also immunoblotted (IB). Assays were performed in duplicate from tissues derived from four mice per genotype
and results are means +− S.E.M. The broken line represents the background activity as measured with pre-immune IgG. (F) AMPKα1 (liver) and AMPKα2 (muscle; EDL) were immunoprecipitated
from wild-type LKB1+ / + ( + / + ) and LKB1S431A/S431A (S431A/S431A) mice and the in vitro kinase activity towards the AMARA peptide was measured. Immunoprecipitates were also immunoblotted.
Assays were performed in duplicate from tissues derived from four mice per genotype and results are means +− S.E.M. The broken line represents the background activity as measured with
pre-immune IgG.
should be noted that previous studies analysing the localization of
endogenous LKB1 were undertaken using immunohistochemistry
[32,53] rather than immunofluorescence, which does not offer
sufficiently high resolution to distinguish between membrane
and cytoplasmic localization [54]. In future work it would be
important to identify antibodies that allow the robust detection
of endogenous LKB1 by immunofluorescence. Nevertheless, our
subcellular fractionation studies indicate that levels of LKB1
associated with the membrane fraction of the liver and MEFs
derived from LKB1C433S/C433S mice were significantly reduced
compared with wild-type mice (Figure 2G). It should be noted
that in these studies the fractionation performed was relatively
crude and the cytoplasmic fraction contained endomembranes
as judged by immunoblotting for ER, endosome and lysosome
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Figure 6 Normal activity of AMPK in MEFs derived from wild-type LKB1+ /+ (+ /+ ) and LKB1S431A/S431A (KI/KI) mice
(A) MEFs were treated with 2 mM AICAR or phenformin for 1 h. AMPKα1 was immunoprecipitated from MEF extracts and the in vitro kinase activity towards the AMARA peptide was measured.
Assays were performed in duplicate for each condition and results are means +− S.E.M. The broken line represents the background activity as measured with pre-immune IgG. MEF extracts were
immunoblotted with the indicated antibodies. No significant basal phosphorylation was observed for the Ser431 site in the LKB1S431A/S431A MEFs (results not shown). #P < 0.05 treated compared with
non-treated cells. Statistical analysis was performed using one-way ANOVA and Tukey’s post-hoc test. There was a normal localization of LKB1 in the liver or MEFs derived from wild-type LKB1+ / +
and LKB1S431A/S431A mice. Livers (B) and MEFs (C) from wild-type LKB1+ / + ( + / + ) and LKB1S431A/S431A (KI/KI) mice were submitted to subcellular fractionation. Cytoplasmic, membrane and
nuclear fractions were immunoblotted with the indicated antibodies. No significant basal phosphorylation was observed for the Ser431 site in the LKB1S431A/S431A liver fractions (results not shown).
The broken line indicates that the samples were processed in parallel on different gels.
markers (Supplementary Figure S2). Therefore our data does
not rule out that the farnesylated LKB1 present within the
cytoplasmic fraction is actually localized to the endomembranes.
Further work is warranted to investigate this. Moreover, the
membrane fraction is a high-speed pellet and probably contains
other non-plasma membrane components. Consistent with this
was also the detected contamination with the ER as indicated by
immunoblotting using the GRP78/Bip marker (Supplementary
Figure S2). Further work would be required to establish whether
LKB1 localized within this fraction was indeed associated with the
plasma membrane. Nevertheless, our finding that in the liver and
MEFs of LKB1C433S/C433S-knockin mice the levels of LKB1 present
within the membrane fraction are significantly reduced supports
previous data that farnesylation serves to promote the membrane
association of LKB1. Our data also reveal that knockin mutation
of Ser431 to alanine or forskolin-induced phosphorylation of Ser431
does not affect LKB1 subcellular fractionation (Figure 6). We
have found relatively small amounts of LKB1 present within the
nuclear subcellular fractions (Figures 2G, 6B and 6C), which
is consistent with previous work that suggests that association
with STRAD and MO25 results in nuclear-exclusion promoting
cytosolic localization and that the vast majority of LKB1 is
believed to be part of this complex [6,35].
Immunoprecipitation studies employing the anti-LKB1
farnesylation-specific antibody indicated that the bulk, if not all,
of the LKB1 expressed in tissues/cells studied (muscle, liver, testis
and brain and MEFs) was farnesylated. Immunoblotting studies
also revealed that LKB1 present in the cytosolic fraction was
similarly farnesylated as the LKB1 present within the membrane
fractions (Figure 2G). Much previous work has established
that farnesylation of proteins serves to facilitate membrane
association, but does not operate to permanently anchor proteins at
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the plasma membrane [27,28]. Thus many farnesylated proteins,
such as LKB1, are frequently localized in the cytosol as well
as other compartments in addition to being found at the plasma
membrane [27,28].
The approach that we employed to raise an antibody against an
in vitro-farnesylated peptide, could be used in the future to raise
other prenylation-specific antibodies to aide with analysing the
roles that this post-translational modification plays more gener-
ally. Our immunoprecipitation studies indicate that the anti-LKB1
farnesylation-specific antibody generated is not selective for
LKB1 and immunoprecipitates at least 13 other proteins termin-
ating with a CAAX motif that are likely to be farnesylated [27,28]
as well as eight Rab GTPases that terminate in a XCXC or XXCC
consensus sequence in which both cysteine residues become
geranylgeranylated [44] (Supplementary Table S2). It is therefore
probable that other farnesylation-specific antibodies raised in the
future would also recognize subgroups of prenylated proteins.
Nevertheless, the anti-LKB1 farnesylation-specific antibody gen-
erated in the present study could have a use in studying prenylation
of some of the other proteins listed in Supplementary Table S1 that
we have found it to recognize. These include DnaJ homologues,
isoforms of Rab, Rap, Ras and Rho, the mitotic regulator spindly,
and the protein kinase MAPKAPK3 that is activated by p38 MKK
(MAPK kinase) [55], which, to our knowledge, has not previously
been reported to be farnesylated, but terminates in a CAAX motif.
Strikingly, in all of the tissues/cells examined (liver, muscle and
MEFs), ablation of LKB1 farnesylation significantly inhibited
both basal and AMPK activity stimulated by treatments such
as AICAR (Figure 3A and Supplementary Figure S4), muscle
contraction (Figures 4A and 4B) and phenformin (Supplementary
Figure S4) that are dependent on LKB1 [10–12,34]. In
LKB1C433S/C433S mice hepatocytes, reduced activation of AMPK
resulted in a significantly blunted suppression of AICAR-induced
lipid synthesis (Figure 3B). The effect on lipid synthesis was most
striking at a low doses of AICAR (50 μM) and was not observed
at the higher doses tested (Figure 3B). It might be possible that
there is a ‘threshold’ for activity required to elicit AMPK/ACC1-
mediated lipid synthesis and thus, even though there is still lower
AMPK activation in LKB1C433S/C433S mice hepatocytes, high doses
of AICAR stimulate AMPK beyond the threshold. This would also
probably explain why the profoundly reduced activation of AMPK
seen following contraction of muscle taken from LKB1C433S/C433S
mice was not sufficient to inhibit glucose uptake (Figures 4C and
4F), as it is known to be very sensitive (i.e. lower ‘threshold’)
to AMPK activation, which is thereby triggered by low levels
of AMPK activation [34,52]. Previous work has shown that in
another mouse model displaying a reduced AMPK activity, in
which LKB1 was expressed at only approximately 10% of the
normal levels in most tissues, these animals were viable and
displayed no overt phenotypes or marked glucose intolerance
[34,56]. Consistent with our observations in muscle taken from
LKB1C433S/C433S mice, contraction of LKB1 hypomorphic muscle
triggered normal glucose uptake despite a significantly reduced
activation of AMPK [34]. Complete knock out of LKB1 in the
muscle was required to inhibit glucose uptake [34,57,58]. Overall,
the moderate reduction in basal, as well as stimulated, AMPK
activity probably explains why LKB1C433S/C433S animals are viable
and display no overt phenotypes or intolerance to glucose or
AICAR (Supplementary Figure S3). We also noticed that the
reduced activation of AMPK in hepatocytes from LKB1C433S/C433S-
knockin mice affected the phosphorylation of raptor, but not ACC
(Figure 3A). This is probably due to ACC being a very good
substrate for AMPK and therefore only a small degree of AMPK
activation is required to trigger maximal phosphorylation of this
substrate.
Figure 7 Schematic representation of the potential mechanism by which
LKB1 farnesylation and myristoylation of AMPKβ might operate to promote
the interaction of LKB1 and AMPK by localizing these enzymes on a two-
dimensional membrane surface
The LKB1–STRAD–MO25 complex is anchored to the membrane through an LKB1 farnesylation
motif. AMPKβ myristoylation promotes the kinase association to the membrane. In the presence
of an increased ratio of AMP/ATP or other metabolic signals that deplete the intracellular ATP
levels, the co-localization of these two kinases at the membrane allows LKB1 to phosphorylate
AMPK on its T-loop residue (Thr172) and thereby fully activates AMPK in response to a metabolic
signal.
An important question concerns the mechanism by which
LKB1 farnesylation promotes the activation of AMPK. In parallel
studies we found that endogenous immunoprecipitated mutant
LKB1[C433S] phosphorylated the artificial substrate LKBtide
peptide and activated the recombinant heterotrimeric AMPK
complex to the same extent as wild-type LKB1 (Figures 2E
and 2F). This indicates that ablation of LKB1 farnesylation
does not affect the intrinsic kinase catalytic activity or ability
of LKB1 to interact with and activate the recombinant AMPK
complex. So how might membrane association of LKB1 promote
activation of AMPK? One possibility is whether the previously
reported co-translational N-terminal myristoylation of Gly2 in
AMPKβ1 [59] and AMPKβ2 [60] could function to co-localize
the AMPK complex and farnesylated LKB1 on a two-dimensional
membrane surface. Myristoylation of proteins has similarities to
farnesylation in that it functions to loosely stabilize the association
of proteins at membranes without permanently fixing them at this
location [61]. If LKB1 and AMPK were co-localized on a two-
dimensional surface of a membrane, this could potentially greatly
boost the efficiency at which these enzymes interact compared
with a three-dimensional environment (Figure 7). Consistent with
the notion that a pool of AMPK is activated at the plasma
membrane, Kemp and colleagues have reported that stimuli that
trigger activation of AMPK via an LKB1-dependent pathway,
such as glucose deprivation, promote the plasma membrane
association of AMPK [60]. Moreover, they observed that mutation
of the myristoylated Gly2 on the AMPKβ subunits inhibited
membrane association as well T-loop Thr172 phosphorylation and
hence the activation of AMPK [60].
Further work is warranted to establish the role that the
myristoylation of AMPKβ subunits plays in regulating membrane
localization and LKB1 phosphorylation. This might be best
addressed by creating knockin mice in which Gly2 of AMPKβ1
and AMPKβ2 is mutated to ablate myristoylation. If a pool of
AMPK was activated by LKB1 at the plasma membrane, there is
some analogy with other signalling systems, such as the PDK1
(phosphoinositide-dependent kinase 1) network. The PDK1 pro-
tein kinase possesses a PH (pleckstrin homology) domain that
promotes membrane association through its ability to interact with
the 3-phosphoinositide second messenger product of the class 1
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PI3K (phosphoinositide 3-kinase) pathway PtdIns(3,4,5)P3 [62].
This helps to localize PDK1 with its Akt substrate that also
possess a PtdIns(3,4,5)P3-binding PH domain at the plasma
membrane. Binding of Akt to PtdIns(3,4,5)P3 induces a marked
conformational change that exposes Thr308 , the residue that PDK1
phosphorylates [62]. In vitro-reconstitution studies showed that
co-localization of PDK1 and Akt on lipid vesicles containing
PtdIns(3,4,5)P3 markedly increased in the efficiency at which
PDK1 can phosphorylate and activate Akt [63,64]. On the basis
of in vitro studies, a knockin mutation that prevents PDK1 from
interacting with PtdIns(3,4,5)P3 was expected to have a major
effect on Akt activation, but instead only reduced Akt activation
∼2-fold in the tissues and cell lines investigated [65,66]. This
magnitude of effect is analogous with the effect that the loss of
farnesylation of LKB1 has on the activation of AMPK observed in
the present study. Subsequent work has revealed that the relatively
small effect on Akt activation of ablating binding of PDK1 to
PtdIns(3,4,5)P3 is probably due to a second mechanism that brings
Akt and PDK1 together and that is mediated by PDK1 possessing
a docking site that recognizes Akt after it is phosphorylated at
Ser473 by mTORC2 (mTOR complex 2) [67]. It is probable that for
the activation of master signalling components, such as Akt and
AMPK, several alternate mechanisms will operate to bring these
enzymes together with their upstream regulators. Thus ablation of
any of these mechanisms individually may only have a moderate
overall effect. The observation that a large 10-fold reduction in
the expression of LKB1 only leads to a relatively small effect on
AMPK [34], emphasizes how efficient the activation of AMPK
by LKB1 is in cells. Promoting the co-localization of LKB1 and
AMPK at the plasma membrane may compromise only one of the
several cellular mechanisms that bring these enzymes together.
As for LKB1, a significant proportion of PDK1 is localized in
the cytoplasm even following the activation of PI3K pathways,
where it plays a critical role in phosphorylating cytosolic
substrates, such as p70 S6K (S6 kinase) and RSK isoforms, that
are not known to reside within membranes. Evidence suggests
that the soluble inositol phosphates, such as inositol(1,3,4,5,6)P5
and InsP6 (inositol hexakisphosphate), which are present at
micromolar levels serve to anchor a portion of cellular PDK1 in
the cytosol as they interact with the PH domain of PDK1 at
nanomolar affinities, thereby preventing PDK1 from interacting
with 3-phosphoinositides at the membrane [68]. It would be
interesting to see if analogous systems operate to anchor LKB1 in
the cytoplasm away from the plasma membrane, for example, by
binding to the prenylation motif. Cytoplasmic LKB1 may have a
key role in the activation of AMPK-related kinases, which our data
suggests is not influenced by LKB1 farnesylation as the activity
of AMPK-related kinases we have assayed was not impaired in
tissues from LKB1C433S/C433S animals.
Previous work has suggested that LKB1 and its phosphorylation
of Ser431 controlled axon specification in the developing nervous
system in response to BDNF by promoting the activation of
the AMPK-related kinases BRSK1/BRSK2 (SAD-B/SAD-A)
[37,38]. This work raised a lot of excitement as it suggested
that phosphorylation of LKB1 at Ser431 was a focal point of
a signalling network that linked extracellular determinants
of neuronal morphogenesis through a cascade of at least five
kinases, TrkB (tropomyosin-related kinase B), PKA, LKB1,
SAD-A and SAD-B, to effectors that polarize neurons [37,38].
The finding that LKB1S431A/S431A mice are viable and display no
obvious overt phenotype or co-ordination/balance abnormalities
does cast doubt on whether phosphorylation of Ser431 is critical
in controlling the regulation of neuronal polarity. For example,
BRSK1/BRSK2 (SAD-B/SAD-A) double-knockout mice that
exhibit a major neuronal polarity phenotype die within 2 h of
birth, display little spontaneous movement and have a weak
response to tactile stimulation [69]. Further work is clearly
warranted to study neuronal polarization and axon specification
in the brain cells/tissue of LKB1S431A/S431A mice. Our finding
that BRSK1/BRSK2 (SAD-B/SAD-A), as well as other AMPK-
related kinases assayed (Supplementary Figure S6), as well as
AMPK are normally active in the brain and other tissues of
LKB1S431A/S431A mice also suggests that phosphorylation of Ser431
is not critical for the activation of these enzymes.
The finding that LKB1[S431A] is normally active is also
consistent with previous work suggesting that mutation of Ser431
has no effect on the catalytic activity or ability of LKB1 to
associate with STRAD and MO25 [6,31,34,35]. In Drosophila
loss-of-function mutations in the LKB1 gene caused defects in
polarity of the oocyte, and this was rescued by low level expression
in the germ line of wild-type LKB1, but not by mutation of the
residue homologous with Ser431 (Ser535) [29]. This observation
might suggests that there would be problems with development
of LKB1S431A/S431A embryos; however, we observe that these mice
were born at the expected Mendelian frequency, suggesting that
mammalian embryonic development is not significantly affected
by ablation of this phosphorylation site (Figure 5B). Interestingly,
the residue equivalent to Ser431 is conserved in all species where
LKB1 has been reported, including C. elegans where the CAAX
motif is not conserved, suggesting strongly that phosphorylation
of this residue must indeed have a significant function. Although
we have failed to observe a phenotype in LKB1S431A/S431A-knockin
mice, it should be stressed that our analysis does not rule out that
the LKB1S431A/S431A or even the LKB1C433S/C433S animals do indeed
display a phenotype that we have not noticed. It is also possible
that significant phenotypes would emerge if the knockin mice
were challenged with conditions that we have not investigated.
Much previous work has also focused on the loss of LKB1 in
tumours. Pathological examination of organs from LKB1S431A/S431A
or LKB1C433S/C433S mice of up to 1 year of age revealed no
detectable spontaneous tumour formation, suggesting that neither
of these mutations alone is sufficient to inhibit the LKB1 tumour-
suppressor function and lead to spontaneous tumour development.
This conclusion is consistent with the data from Fogarty and
Hardie [36] that showed that overexpression in HeLa cells (that
lack LKB1 expression) of LKB1[S431A] together with STRAD
and MO25 inhibited the cell cycle to the same extent as wild-
type LKB1. In future work it would be of interest to cross
LKB1S431A/S431A or LKB1C433S/C433S mice with tumour-prone mice
to investigate whether these mutations have any effect on the
ability of LKB1 to operate as a tumour suppressor.
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Investigation of LKB1 Ser431 phosphorylation and Cys433 farnesylation using
mouse knockin analysis reveals an unexpected role of prenylation in
regulating AMPK activity
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Figure S1 Immunoprecipitation studies using the anti-LKB1 farnesylation-specific antibody from the muscle, liver, brain and testis as well as MEFs taken
from wild-type LKB1+ /+ (+ /+ ) and LKB1C433S/C433S (KI/KI) mice
Immunoprecipitates (IP), as well as immunoprecipitate supernatants and total lysates, were subjected to immunoblotting using anti-LKB1 and anti-LKB1 farnesylation-specific (LKB1 Farn C433)
antibodies. The arrows indicate farnesylated C433 LKB1. Molecular mass is given on the left-hand side in kDa. HOM, homozygous LKB1C431/C431; WT, wild-type.
1 Correspondence may be addressed to either of these authors (email v.houde@dundee.ac.uk or d.r.alessi@dundee.ac.uk).
2 Current address: Nestle´ Institute of Health Sciences SA, Campus EPFL Quartier de l’innovation, baˆtiment G 1015 Lausanne, Switzerland.
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Figure S2 Liver cytoplasmic and membrane fractions from wild-type
LKB1+ /+ (+ /+ ) and LKB1C433S/C433S (KI/KI) mice were immunoblotted with
the indicated antibodies to determine the presence of endomembranes
(endosomes, lysosomes and ER) in the cytoplasmic fraction preparation
Molecular mass is given on the left-hand side in kDa.
Figure S3 Glucose metabolism in 2-month-old LKB1C433S/C433S mice
(A) Glucose tolerance test. Blood glucose concentration was measured from 2-month-old
male wild-type LKB1+ / + and LKB1C433S/C433S knockin mice fasted for 6 h and injected
intraperitoneally with glucose (2 g/kg of body mass). Results are the means +− S.E.M. (n = 4).
(B) AICAR tolerance test. Blood glucose concentration was measured from 2-month-old
male wild-type LKB1+ / + and LKB1C433S/C433S knockin mice fasted for 6 h and injected
intraperitoneally with AICAR (250 mg/kg of body mass). Results are the means +− S.E.M. (n = 4).
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Figure S4 Impaired activity of AMPK in MEFs derived from wild-type LKB1+ /+ (+ /+ ) and LKB1C433S/C433S (KI/KI) mice
MEFs were treated with 2 mM AICAR or phenformin for 1 h. AMPKα1 was immunoprecipitated from MEF extracts and the in vitro kinase activity towards the AMARA peptide was measured.
Assays were performed in duplicate for each condition and results are means +− S.E.M. The broken line represents the background activity as measured with pre-immune IgG. MEF extracts were
immunoblotted with the indicated antibodies. *P < 0.05 LKB1+ / + compared with LKB1C433S/C433S mice within each condition. #P < 0.05 treated compared with non-treated cells. Statistical analysis
was performed using one-way ANOVA and Tukey’s post-hoc test. LKB1 Farn C433, anti-LKB1 farnesylation-specific antibody.
c© The Authors Journal compilation c© 2014 Biochemical Society
V. P. Houde and others
Figure S5 Activity of AMPK-related kinases in mouse tissues taken from wild-type LKB1+ /+ and LKB1C433S/C433S mice
(A) SIK3 was immunoprecipitated (IP) from liver and muscle (EDL) from wild-type LKB1+ / + ( + / + ) and LKB1C433S/C433S (C433S/C433S) mice and the in vitro kinase activity towards the
Sakamototide peptide was measured. Immunoprecipitates were also immunoblotted (IB). Assays were performed in duplicate from tissues taken from six mice per genotype and results are
means +− S.E.M. (B) as in (A), except that NUAK1 was immunoprecipitated. (C) As in (A), except that MARK4 was immunoprecipitated. The broken line represents the background activity as measured
with pre-immune IgG. All P values for the differences between LKB1+ / + compared with LKB1C433S/C433S mice were not significant.
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Figure S6 Activity of AMPK-related kinases in mouse tissues taken from wild-type LKB1+ /+ and LKB1S431A/S431A mice
(A) SIK3 was immunoprecipitated (IP) from liver and muscle (EDL) from wild-type LKB1+ / + ( + / + ) and LKB1S431A/S431A (S431A/S431A) mice and the in vitro kinase activity towards the
Sakamototide peptide was measured. Immunoprecipitates were also immunoblotted (IB). Assays were performed in duplicate from tissues derived from four mice per genotype and results are
means +− S.E.M. (B) as in (A), except that NUAK1 was immunoprecipitated. (C) As in (A), except that BRSK1/BRSK2 was immunoprecipitated. The broken line represents the background activity as
measured with pre-immune IgG. All P values for the differences between LKB1+ / + compared with LKB1C433S/C433S mice were not significant.
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Table S1 Endogenous LKB1 was immunoprecipitated with the anti-LKB1 farnesylation-specific antibody in samples of mice liver, muscle, brain and testis
and MEFs derived from wild-type and C433S/C433S knockin mice and analysed by MS to identify potential binding/interacting proteins
Results are representative data from two independent experiments. The proteins listed below are known to be prenylated (farnesylated or geranylgeranylated) except for MO25, STRAD and MAPKAPK3.
(a) Liver
Liver LKB1+ / + Liver LKB1C433S/C433S
Protein name Mascot score Number of peptides Mascot score Number of peptides SwissProt accession number
LKB1 1012 64 Q9WTK7
MO25 1216 91 Q06138
STRADα 287 21 Q3UUJ4
STRADβ 899 49 Q8K4T3
DnaJ homologue subfamily A member 2 1238 100 878 73 Q9QYJ0
DnaJ homologue subfamily A member 1 2016 136 1658 124 P63037
Ras-related protein Rap2A 758 33 531 33 Q80ZJ1
Rab14 226 19 244 20 Q91V41
Rab35 198 10 192 9 Q6PHN9
(b) Muscle
Muscle LKB1+ / + Muscle LKB1C433S/C433S
Protein name Mascot score Number of peptides Mascot score Number of peptides SwissProt accession number
LKB1 698 54 Q9WTK7
MO25 891 86 Q06138
STRADα 113 14 Q3UUJ4
STRADβ 569 37 Q8K4T3
DnaJ homologue subfamily A member 2 1857 138 457 55 Q9QYJ0
MAPKAPK3 787 66 104 17 Q3UMW7
(c) Brain
Brain LKB1+ / + Brain LKB1C433S/C433S
Protein name Mascot score Number of peptides Mascot score Number of peptides SwissProt accession number
LKB1 3228 184 Q9WTK7
MO25 3166 173 Q06138
STRADα 2013 152 Q3UUJ4
STRADβ 689 30 Q8K4T3
DnaJ homologue subfamily A member 2 1885 122 Q9QYJ0
DnaJ homologue subfamily A member 1 1144 78 P63037
Ras-related protein Rap2A 758 33 531 33 Q80ZJ1
Rap2C 431 18 289 21 Q8BU31
Rheb 350 24 266 25 Q921J2
HRAS 195 10 77 6 Q61411
Rab8A 164 10 176 7 P55258
Rab6B 233 16 193 15 P61294
Rab10 228 13 199 8 P61027
NRAS 148 10 199 16 P08556
Rho-related GTP-binding protein RhoG 52 2 82 6 P84096
(d) Testis
Testis LKB1+ / + Testis LKB1C433S/C433S
Protein name Mascot score Number of peptides Mascot score Number of peptides SwissProt accession number
LKB1 1574 103 Q9WTK7
MO25 2588 131 Q06138
STRADα 1614 120 Q3UUJ4
STRADβ 246 20 Q8K4T3
DnaJ homologue subfamily A member 2 2597 161 2630 229 Q9QYJ0
DnaJ homologue subfamily A member 1 2280 122 2578 176 P63037
Rab33B 87 3 70 2 O35963
Rab39A 87 2 70 2 Q8BHD0
Rab15 87 2 73 4 Q8K386
Rab18 173 12 105 7 P35293
Rab35 134 7 73 4 Q6PHN9
Rab1b 100 9 73 9 Q9D1G1
Rab8A 99 6 73 6 P55258
MAPKAPK3 56 11 99 14 Q3UMW7
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Table S1 Continued
(e) MEFs
MEF LKB1+ / + MEF LKB1C433S/C433S
Protein name Mascot score Number of peptides Mascot score Number of peptides SwissProt accession number
LKB1 1384 64 Q9WTK7
MO25 1328 76 Q06138
STRADα 1094 62 Q3UUJ4
STRADβ 48 5 Q8K4T3
DnaJ homologue subfamily A member 2 1591 118 1170 70 Q9QYJ0
DnaJ homologue subfamily A member 1 1039 54 727 40 P63037
Spindly 536 40 447 32 Q923A2
MAPKAPK3 149 12 330 23 Q3UMW7
Rho-related GTP-binding protein RhoC 570 26 416 16 Q62159
Rab18 143 3 231 8 P35293
Rab35 120 3 101 5 Q6PHN9
Table S2 Sequence alignment of proteins with the CAAX motif that have
been immunoprecipitated with the anti-LKB1 farnesylation-specific antibody
from tissues or MEFs derived from wild-type and C433S/C433S knockin mice
The C-terminal cysteine (C) is the residue that is prenylated, A is any aliphatic amino acid and
X determines if the protein is farnesylated (X = M, S, Q, A or C) or geranylgeranylated (X = L
or E).
Protein name Protein motif
Alignment of the last six
amino acids
LKB1 CAAX SACKQQ
DnaJ homologue subfamily A member 2 CAAX VQCAHQ
DnaJ homologue subfamily A member 1 CAAX VQCQTS
Ras-related protein Rap2A CAAX SACNIQ
HRAS CAAX CKCVLS
NRAS CAAX SPCVLM
Rheb CAAX SSCSVM
Rap2C CAAX TTCVVQ
Rho-related GTP-binding protein RhoG CAAX RSCILL
Rho-related GTP-binding protein RhoC CAAX RGCPIL
Rab18 CAAX GYCSVL
Rab8A CAAX FRCSLL
MAPKAPK3 CAAX QGCNNQ
Spindly CAAX TQCSQQ
Rab35 XCC RKKRCC
Rab10 XCC WKSKCC
Rab1B XCC ASGGCC
Rab14 CXC REGCGC
Rab6B CXC EGGCSC
Rab15 CXC SKTCWC
Rab33B CXC AVTCWC
Rab39A CXC RKECFC
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